MVGAE: A Multi-View Graph Auto-Encoder Model for Drug Prediction of Non-Small Cell Lung Cancer Based on Synthetic

Shaobo Hu1, Runsheng Jiang1, Ning Zhao1

  • 1College of Computer and Control Engineering, Northeast Forestry University, No. 26 Hexing Road, Harbin 150040, China.

Insights

This study introduces a computational framework to identify new non-small cell lung cancer (NSCLC) treatments. It predicts driver genes, synthetic lethality targets, and potential drugs for precision medicine.

Area of Science:

  • Computational biology
  • Genomics
  • Drug discovery

Background:

  • Non-small cell lung cancer (NSCLC) requires novel therapeutic targets and drugs.
  • Existing methods for identifying therapeutic targets and drugs are limited.

Purpose of the Study:

  • To develop an integrated computational framework for identifying therapeutic target genes and drugs for NSCLC.
  • To leverage multi-source biological network data for enhanced data mining and prediction.

Main Methods:

  • Utilized a multi-view graph auto-encoder (MVGAE) model integrated with network-informed adaptive positive-unlabeled (NIAPU) and synthetic lethality multi-view graph auto-encoder (SLMGAE) models.
  • Integrated protein-protein interaction networks, disease-gene associations, and gene-drug bipartite graphs.
  • Employed computational screening to predict driver genes, synthetic lethality targets, and candidate drugs.

Main Results:

  • Identified seven potential driver genes associated with NSCLC using the NIAPU model.
  • Predicted nine genes with synthetic lethality (SL) interactions as candidate therapeutic targets using SLMGAE.
  • Predicted corresponding targeted drugs for SL targets using MVGAE, with some targets (e.g., ATR, RAD51) showing conditional SL effects and some drugs (e.g., PAZOPANIB) previously linked to NSCLC treatment.

Conclusions:

  • The integrated MVGAE framework effectively prioritizes potential therapeutic targets and candidate drugs for NSCLC.
  • This approach offers a robust computational basis for drug repurposing and precision treatment strategies in NSCLC.
  • The study highlights the potential of integrating complementary models for advancing NSCLC therapy.

Related Concept Videos

Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
63
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
168
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.4K